Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(5 sites)
United States
Stanford University, Stanford, California Indiana University, Indianapolis, Indiana Mayo Clinic, Rochester, Minnesota Ohio State University, Columbus, Ohio University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania